Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects

Trial Profile

Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Zika virus vaccine-Sanofi (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Dec 2017 Preliminary results assessing the early safety and immunogenicity of Zika-virus-vaccine in the phase I trials (NCT02963909, NCT02952833, and NCT02937233; n=68) published in The Lancet.
    • 04 Dec 2017 Preliminary results from three phase I trial (NCT02963909, NCT02952833, and NCT02937233; n=68) presented in a Walter Reed Army Institute of Research media release.
    • 29 Jun 2017 Planned End Date changed from 5 Feb 2018 to 2 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top